ALNYLAM PHARMACEUTICALS INC COM USD0.01 revenue breakdown overview

ALNYLAM PHARMACEUTICALS INC COM USD0.01 revenue for the last year amounted to 2.25 B USD, the most of which — 2.25 B USD — came from its highest performing source at the moment, Ribonucleic Acid Interference Therapeutics, the year earlier bringing 1.83 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought ALNYLAM PHARMACEUTICALS INC COM USD0.01 1.54 B USD, and the year before that — 1.28 B USD.